Ipsen Group news

Ipsen receives positive CHMP opinion recommending Cabometyx® in combination with Opdivo® as first-line treatment for patients living with advanced renal cell carcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) for the first-line treatment of advanced renal cell carcinoma (aRCC). The European Commission, which has the authority to approve medicines for the European Union (E.U.), will n

Feb. 26, yyyy